Španielsko - španielčina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios cinfa s.a. - levonorgestrel; etinilestradiol - comprimido recubierto con pelÍcula - 0,1 mg/0,02 mg - levonorgestrel 0,1 mg; etinilestradiol 0,02 mg - levonorgestrel y estrógeno

Španielsko - španielčina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios francisco durban s.a. - levonorgestrel; etinilestradiol - comprimido recubierto - 0,1 mg/0,02 mg - levonorgestrel 0,1 mg; etinilestradiol 0,02 mg - levonorgestrel y estrógeno

Španielsko - španielčina - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios francisco durban s.a. - levonorgestrel; etinilestradiol - comprimido recubierto - 0,1 mg/0,02 mg - levonorgestrel 0,1 mg; etinilestradiol 0,02 mg - levonorgestrel y estrógeno

Holandsko - holandčina - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - ethinylestradiol 0,02 mg/stuk ; levonorgestrel 0,1 mg/stuk - filmomhulde tablet - allurarood ac aluminium lak (e 129) ; ijzeroxide geel (e 172) ; indigokarmijn aluminiumlak (e 132) ; lactose 0-water ; lecithine, soya (e 322) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; povidon k 30 (e 1201) ; talk (e 553 b) ; titaandioxide (e 171), - levonorgestrel and ethinylestradiol

Holandsko - holandčina - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

aurobindo pharma b.v. baarnsche dijk 1 3741 ln baarn - ethinylestradiol 30 µg/stuk ; levonorgestrel 150 µg/stuk - filmomhulde tablet - crospovidon (e 1202) ; ijzeroxide geel (e 172) ; lactose 1-water ; macrogol 3350 ; magnesiumstearaat (e 470b) ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; povidon k 30 (e 1201) ; talk (e 553 b) ; titaandioxide (e 171), - levonorgestrel and ethinylestradiol

Spojené štáty - angličtina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology: clinical studies). - the mainstays for decreasing the risk of

Spojené štáty - angličtina - NLM (National Library of Medicine)

golden state medical supply, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets usp are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies .) the mainstays for d

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets are indicated in the: estrogens should not be used in individuals with any of the following conditions:

Spojené štáty - angličtina - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) the mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin d intake, and when indicated, pharmacologic therapy. postmenopausal women require an average of 1500 mg/day of elemental calcium. therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. vitamin d supplementation of 400 to 800 iu/day may also be required to ensure adequate daily intake in postmenopausal women. estrogens should not be used in individuals with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction. - liver dysfunction or disease. - estradiol tablets should not be used in patients with known hypersensitivity to its ingredients. estradiol tablets 2 mg contain fd&c yellow no. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. although the overall incidence of fd&c yellow no. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity. - known or suspected pregnancy. there is no indication for estradiol tablets in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions .)

Spojené štáty - angličtina - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - ethinyl estradiol 0.02 mg - levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets are indicated for use by females of reproductive potential to prevent pregnancy. levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: risk summary there is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb reduction defects) following exposure to cocs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. contraceptive hormones and/or metabolites are present in human milk. cocs can red